2型糖尿病门诊患者晚期肝纤维化常见,需系统筛查
本研究在561例不知晓脂肪肝的2型糖尿病门诊患者中,用弹性成像筛查脂肪变和纤维化。脂肪变患病率70%,纤维化(LSM≥7.0 kPa)21%,中重度纤维化(F2及以上)15%。结果支持ADA指南对T2DM伴脂肪变或ALT升高者筛查临床显著纤维化。
要点
- T2DM门诊患者中脂肪变患病率70%,纤维化21%。
- 中重度纤维化(F2及以上)影响至少15%的T2DM患者。
- AST/ALT单独筛查不足,需结合弹性成像和FIB-4/APRI。
核心结论
- 中重度纤维化(F2及以上)影响至少六分之一(15%)的T2DM患者。
- 结果支持ADA指南对T2DM伴脂肪变或ALT升高者筛查临床显著纤维化。
研究设计与样本
- 招募561例不知晓脂肪肝的T2DM门诊患者(年龄60±11岁,BMI 33.4±6.2 kg/m2,HbA1c 7.5±1.8%)。
- 用受控衰减参数(≥274 dB/m)和肝硬度测量(LSM≥7.0 kPa)筛查脂肪变和纤维化。
- 排除其他肝病病因,并测量APRI和FIB-4,必要时行肝活检。
主要发现
- 脂肪变患病率70%,纤维化(LSM≥7.0 kPa)患病率21%。
- 中度纤维化(F2:LSM≥8.2 kPa)占6%,重度纤维化或肝硬化(F3-4:LSM≥9.7 kPa)占9%。
- FIB-4和APRI面板估计与LSM结果相似,无创检测与肝活检结果一致。
- 脂肪变患者中AST或ALT≥40 units/L者分别占8%和13%;纤维化患者中分别占18%和28%。
关键数值与推荐
- 脂肪变诊断阈值:受控衰减参数≥274 dB/m。
- 纤维化诊断阈值:LSM≥7.0 kPa;中度纤维化F2:LSM≥8.2 kPa;重度纤维化或肝硬化F3-4:LSM≥9.7 kPa。
- AST或ALT≥40 units/L作为异常阈值。
临床怎么用
- 对T2DM患者应系统筛查NAFLD和纤维化,尤其伴脂肪变或ALT升高者。
- AST/ALT单独不足以初始筛查,应结合弹性成像和FIB-4/APRI等无创面板。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Assess the prevalence of nonalcoholic fatty liver disease (NAFLD) and of liver fibrosis associated with nonalcoholic steatohepatitis in unselected patients with type 2 diabetes mellitus (T2DM). RESEARCH DESIGN AND METHODS: A total of 561 patients with T2DM (age: 60 ± 11 years; BMI: 33.4 ± 6.2 kg/m2; and HbA1c: 7.5 ± 1.8%) attending primary care or endocrinology outpatient clinics and unaware of having NAFLD were recruited. At the visit, volunteers were invited to be screened by elastography for steatosis and fibrosis by controlled attenuation parameter (≥274 dB/m) and liver stiffness measurement (LSM; ≥7.0 kPa), respectively. Secondary causes of liver disease were ruled out. Diagnostic panels for prediction of advanced fibrosis, such as AST-to-platelet ratio index (APRI) and Fibrosis-4 (FIB-4) index, were also measured. A liver biopsy was performed if results were suggestive of fibrosis. RESULTS: The prevalence of steatosis was 70% and of fibrosis 21% (LSM ≥7.0 kPa). Moderate fibrosis (F2: LSM ≥8.2 kPa) was present in 6% and severe fibrosis or cirrhosis (F3-4: LSM ≥9.7 kPa) in 9%, similar to that estimated by FIB-4 and APRI panels. Noninvasive testing was consistent with liver biopsy results. Elevated AST or ALT ≥40 units/L was present in a minority of patients with steatosis (8% and 13%, respectively) or with liver fibrosis (18% and 28%, respectively). This suggests that AST/ALT alone are insufficient as initial screening. However, performance may be enhanced by imaging (e.g., transient elastography) and plasma diagnostic panels (e.g., FIB-4 and APRI). CONCLUSIONS: Moderate-to-advanced fibrosis (F2 or higher), an established risk factor for cirrhosis and overall mortality, affects at least one out of six (15%) patients with T2DM. These results support the American Diabetes Association guidelines to screen for clinically significant fibrosis in patients with T2DM with steatosis or elevated ALT.
引用
- Lomonaco R, Godinez Leiva E, Bril F, et al. Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening. Diabetes Care. 2020. PMID: 33355256. doi:10.2337/dc20-1997
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。